Cogent Biosciences (COGT) Competitors $5.42 +0.21 (+3.93%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. BHVN, AAPG, KYMR, CGON, MTSR, MIRM, BHC, BEAM, GMTX, and NAMSShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Biohaven (BHVN), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), CG Oncology (CGON), Metsera (MTSR), Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Biohaven Ascentage Pharma Group International Kymera Therapeutics CG Oncology Metsera Mirum Pharmaceuticals Bausch Health Companies Beam Therapeutics Gemini Therapeutics NewAmsterdam Pharma Biohaven (NYSE:BHVN) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Is BHVN or COGT more profitable? Cogent Biosciences' return on equity of -112.55% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets BiohavenN/A -225.12% -158.89% Cogent Biosciences N/A -112.55%-60.44% Does the media favor BHVN or COGT? In the previous week, Biohaven had 8 more articles in the media than Cogent Biosciences. MarketBeat recorded 21 mentions for Biohaven and 13 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.88 beat Biohaven's score of 0.70 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, BHVN or COGT? Cogent Biosciences is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiohavenN/AN/A-$408.17M-$9.39-2.38Cogent BiosciencesN/AN/A-$192.41M-$1.94-2.79 Do insiders and institutionals hold more shares of BHVN or COGT? 88.8% of Biohaven shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 5.9% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor BHVN or COGT? Biohaven received 118 more outperform votes than Cogent Biosciences when rated by MarketBeat users. However, 70.22% of users gave Cogent Biosciences an outperform vote while only 67.44% of users gave Biohaven an outperform vote. CompanyUnderperformOutperformBiohavenOutperform Votes40867.44% Underperform Votes19732.56% Cogent BiosciencesOutperform Votes29070.22% Underperform Votes12329.78% Which has more risk and volatility, BHVN or COGT? Biohaven has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Cogent Biosciences has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Do analysts prefer BHVN or COGT? Biohaven currently has a consensus target price of $62.54, indicating a potential upside of 180.13%. Cogent Biosciences has a consensus target price of $14.43, indicating a potential upside of 166.46%. Given Biohaven's stronger consensus rating and higher possible upside, research analysts plainly believe Biohaven is more favorable than Cogent Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryCogent Biosciences beats Biohaven on 8 of the 15 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$615.96M$6.74B$5.50B$7.96BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-2.187.3822.6318.55Price / SalesN/A241.88397.30103.38Price / CashN/A65.8538.1834.62Price / Book2.356.476.704.25Net Income-$192.41M$143.68M$3.23B$248.27M7 Day Performance20.07%1.85%1.36%1.28%1 Month Performance-6.48%6.73%3.85%3.75%1 Year Performance-21.86%-2.72%15.87%5.31% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences2.2046 of 5 stars$5.42+3.9%$14.43+166.5%-19.8%$615.96MN/A-2.1880Upcoming EarningsOptions VolumeAnalyst RevisionBHVNBiohaven3.6265 of 5 stars$21.76+9.7%$62.54+187.4%-43.0%$2.22BN/A-2.33239Upcoming EarningsAnalyst ForecastHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$25.29-3.8%N/AN/A$2.20B$980.65M0.00600KYMRKymera Therapeutics2.0027 of 5 stars$33.61+1.1%$56.36+67.7%+1.9%$2.18B$47.07M-14.36170News CoveragePositive NewsCGONCG Oncology2.1169 of 5 stars$27.97+25.0%$59.33+112.1%-33.0%$2.13B$1.14M-19.7061Upcoming EarningsAnalyst ForecastNews CoverageHigh Trading VolumeMTSRMetseraN/A$19.81+6.9%$47.00+137.3%N/A$2.08BN/A0.0081News CoverageMIRMMirum Pharmaceuticals4.2515 of 5 stars$41.31+1.3%$58.20+40.9%+73.0%$2.04B$336.89M-20.45140Upcoming EarningsNews CoveragePositive NewsBHCBausch Health Companies4.1825 of 5 stars$5.41-0.6%$7.17+32.5%-39.7%$2.00B$9.63B-45.0819,900Analyst UpgradeNews CoverageBEAMBeam Therapeutics3.0691 of 5 stars$19.80+1.4%$49.45+149.8%-6.1%$1.99B$63.52M-11.25510Upcoming EarningsShort Interest ↑GMTXGemini TherapeuticsN/A$45.42-1.6%N/A+66.7%$1.97BN/A-45.4230NAMSNewAmsterdam Pharma3.1636 of 5 stars$17.83+1.8%$43.33+143.0%-12.3%$1.96B$45.56M-6.864Positive News Related Companies and Tools Related Companies Biohaven Alternatives Ascentage Pharma Group International Alternatives Kymera Therapeutics Alternatives CG Oncology Alternatives Metsera Alternatives Mirum Pharmaceuticals Alternatives Bausch Health Companies Alternatives Beam Therapeutics Alternatives Gemini Therapeutics Alternatives NewAmsterdam Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COGT Stock Free COGT Stock Alerts